Open AccessLack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial
Author(s) -
Daniel Roche,
Constantine J. Trela,
Maria Argos,
Farzana Jasmine,
Muhammad G. Kibriya,
Habibul Ahsan,
Andrea C. King
Publication year - 2019
Publication title -
alcohol and alcoholism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.747
H-Index - 99
eISSN - 1464-3502
pISSN - 0735-0414
DOI - 10.1093/alcalc/agz046
Subject(s) - naltrexone , smoking cessation , single nucleotide polymorphism , opioid , nicotine , medicine , randomized controlled trial , snp , context (archaeology) , psychology , genotype , biology , receptor , genetics , gene , paleontology , pathology
The present study examined how variation in mu- (OPRM1), kappa- (OPRK), and delta- (OPRD) opioid receptor genes may influence the efficacy of naltrexone in the context of a smoking cessation trial.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom